The Patent Finder

Matrix Pharmacorp Private Limited

27 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
12
Ending by 2030
Oct 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 6 to 27, 2027 · next Feb 6
  • 1 fee due Apr 15, 2027
    The maintenance fee for Process of Making Regadenoson and Novel Polymorph Thereof (US 10,442,832) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
  • 2 fees due May 19 to 26, 2027 · next May 19
  • 1 fee due Jun 30, 2027
    The maintenance fee for Process and Novel Polymorphic Form of Vortioxetine and Its Pharmaceutically Acceptable Salts (US 10,519,121) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Aug 18, 2027
    The maintenance fee for Amorphous trisodium sacubitril valsartan and a process for the preparation thereof (US 10,562,866) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,143,435One pot process for the preparation of candesartan
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,344,159Carvedilol phosphate sesquihydrate
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,288,401Polymorphic forms
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,026,356Process for the large scale production of Stavudine
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,048,904Process for the preparation of olmesartan medoxomil
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,258,312Process for preparing pure valsartan
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,309,723Preparation of Zopiclone and its enantiomerically enriched isomer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,318,930Process for preparing polymorphic forms of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,329,952Process for the preparation of O-desmethylvenlafaxine succinate polymorphic forms
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,350,030Process for producing 5-fluoro-1-(2R, 5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited